Castle Biosciences (CSTL) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1 year price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $41.00. On average, they anticipate the company's share price to reach $32.29 in the next twelve months. This suggests a possible upside of 95.4% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.

Castle Biosciences' stock was trading at $23.54 on January 1st, 2023. Since then, CSTL shares have decreased by 29.8% and is now trading at $16.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CSTL earnings forecast.

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.31. The firm had revenue of $50.14 million for the quarter, compared to analysts' expectations of $43.51 million. Castle Biosciences had a negative net margin of 53.04% and a negative trailing twelve-month return on equity of 22.57%.

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

(CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Castle Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.51%), Granahan Investment Management LLC (9.43%), BlackRock Inc. (7.95%), Principal Financial Group Inc. (5.07%), Bellevue Group AG (4.19%) and Palisade Capital Management LP (2.25%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends.

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSTL stock can currently be purchased for approximately $16.52.

Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $442.90 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

The company employs 582 workers across the globe.

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com.